

Modulation of Uterine Phospholipase A₂ Activity by Estradiol During the Delayed Implantation Process in Rats

Michung Yoon*, Changmee Kim*, Rim Soon Choe** and Kyungza Ryu

Department of Pharmacology and Endocrine Laboratory, College of Medicine and Department of Biology**, College of Science, Yonsei University, Seoul 120-749, Korea*

ABSTRACT

The present study was performed to determine whether estradiol, via cAMP mediation, induces prostaglandin synthesis by modulating phospholipase A₂ activity which hydrolyzes phospholipids into arachidonic acids, a precursor for prostaglandin synthesis, during the implantation process in rats. Uterine phospholipase A₂ activity was elevated on day 5 of pregnancy when implantation normally occurs in rats. Moreover, phospholipase A₂ activity was higher in the implant sites than in the non-implant sites of uterus on day 6. In delayed implantation model, phospholipase A₂ activity was increased at 12 hrs after estradiol administration and at 8 hrs after dbcAMP administration. In addition, higher activity of phospholipase A₂ was induced by the treatment of estradiol plus theophylline, compared with estradiol-only treated group. The simultaneous treatment of indomethacin with estradiol or dbcAMP did not alter phospholipase A₂ activity compared with estradiol or dbcAMP-only treated group although significant suppression was observed in uterine PGE and PGF_{2α} concentrations. These results suggest that estradiol or cAMP stimulates uterine phospholipase A₂ activity, thereby increasing prostaglandin synthesis during the implantation process in rats.

Key Words: Estradiol, cAMP, Phospholipase A₂, Prostaglandins, Implantation

INTRODUCTION

Prostaglandins (PGs) are known to regulate several uterine functions including implantation of the blastocysts. It was demonstrated that uterine PGE and PGF_{2α} concentrations were sharply increased during the implantation period (Phillips and Poyser, 1981; Lee *et al.*, 1985; Yoon and Ryu, 1987) and levels were significantly greater in the implant sites than in the non-implant sites of uterus (Kennedy, 1977; Yoon and Ryu, 1987). In addition, estradiol appears to stimulate uterine PG synthesis during the implantation process (Dey *et al.*, 1982; Pakrasi *et al.*, 1983; Yoon *et al.*, 1991) and this process may be mediated by the elevation of uterine cAMP lev-

els (Yoon *et al.*, 1991).

However, the mechanism by which estradiol or cAMP modulates uterine PG synthesis during the implantation process has not been clearly defined. Phospholipase A₂ (PLA₂) which hydrolyzes phospholipids into arachidonic acid is known to serve as a rate-limiting enzyme for PG synthesis. Evidence that PLA₂ activity can be modulated by ovarian steroids (Dey and Johnson, 1980; Dey *et al.*, 1982; Pakrasi *et al.*, 1983) suggests possible effects of estradiol and progesterone on this enzyme in uterine PG synthesis during the implantation process.

The present study was performed to determine whether estradiol, via cAMP mediation, induces uterine PG synthesis by modulating phospholipase A₂ activity during the implantation process in rats.

MATERIALS AND METHODS

Experimental groups

Female Sprague Dawley rats aged 2~3 months, weighing 200-250 g were used throughout this study. The morning in which sperm was found in the vagina was designated as day 1 of pregnancy.

Group 1: Uterine PLA₂ activity was measured during normal pregnancy which implantation occurs on day 5 of pregnancy. PLA₂ activity was also measured in the implant sites and the non-implant sites of uterus on days 6 and 7 of pregnancy.

Group 2: Uterine PLA₂ activity was measured during the delayed implantation period. Delayed implantation was induced by ovariectomy on day 3 of pregnancy, followed by a daily injection of progesterone (3 mg/0.2 ml in sesame oil) on days 3-7 and a single injection of estradiol (1 ug/0.1 ml in sesame oil) on day 8. Delayed implantation occurred by 24 hrs after estradiol treatment. Instead of estradiol on day 8 of pregnancy, 50 ul of 50 mM dbcAMP dissolved in PBS (0.01 M phosphate, 0.15 M NaCl, pH 7.0) was administered by an intrauterine instillation. To confirm the effect of cAMP, 100 mM theophylline (100 ul/uterine horn) was administered by an intrauterine instillation 2 hrs prior to estradiol administration during the delayed implantation process.

Group 3: Uterine PLA₂ activity was also measured after simultaneous treatment of indomethacin (2 mg/0.2 ml in sesame oil) with estradiol or dbcAMP on day 8 of pregnancy.

Just prior to intrauterine instillation, a cotton ligature was placed around the upper cervix to minimize the escape of fluid. At sacrifice, uterine tissues were immersed in cold saline containing 6 mM theophylline and indomethacin (10 ug/ml). Implant sites were identified at 24 hrs after the treatment of estradiol or dbcAMP and uteri were cut into the implant sites and the non-implant sites.

Determination of uterine PGs

Uterine tissues were homogenized (Polytron homogenizer, Janke & Kunkel, W. Germany) in 1 ml PBS and 3 ml ethyl acetate: isopropanol:

0.2 N HCl (3:1:1, V/V/V) solution. After vortexing for 15 sec twice, 2 ml ethyl acetate and 3 ml distilled water were added. After mixing, phases were separated by centrifugation. The organic phase (3-3.5 ml) was transferred to a test tube and dried by vortex evaporator. The residue was dissolved in gel Tris buffer. Concentrations of PGE and PGF₂ were measured by radioimmunoassay (Clinical Assays, USA).

Determination of phospholipase A₂ activity

Uterine tissues were homogenized in ice-cold PBS (pH 7.4). The homogenate was centrifuged at 750 × g (4°C) for 15 min and the supernatant was assayed for enzyme activity. Unlabeled dipalmitoyl-phosphatidylcholine and labeled dipalmitoyl-1-¹⁴C-phosphatidylcholine (NEN, USA) were served as substrates.

100 ul of 80 nM unlabeled substrate, 100 ul of labeled substrate (10,000 cpm, 115.8 mCi/mmol) which were dissolved in 50 mM HEPES buffer containing 10 mM CaCl₂ and 100 ul of the same buffer were mixed and placed in a boiling water bath for 1 min. To this mixture, 300 ul of enzyme source (400 ug protein) was added and the reaction was run for 1 hr at 37°C. After incubation was stopped by addition of 2 ml Dole's reagent (0.33 N H₂SO₄: isopropanol: heptane = 28:36:36), the mixture was heated to 60°C for 1 min and then cooled to room temperature. After 1 ml distilled water and 2 ml heptane were added, the mixture was centrifuged at 1,000 × g for 15 min and the aqueous layer was frozen in an acetone-dry ice. The non-aqueous layer was decanted into a tube containing 100-150 mg of silicic acid (100~300 mesh) and content in a tube was mixed for 30 sec on vortex and centrifuged at 1,600 × g for 15 min. The radioactivity of liberated ¹⁴C-palmitate from the top layer was counted in a β-counter. The activity was expressed as nmol of fatty acid released per hr per mg protein.

The differences between the experimental groups were analyzed by one-way ANOVA with t-test, and P values less than 0.05 were considered significant.

RESULTS

Uterine phospholipase A₂ activity during early pregnancy

Uterine PLA₂ activity was measured during early pregnancy (Fig. 1). PLA₂ activity was 9.03 ± 1.82 nmol/mg protein/h on day 1 of pregnancy and decreased to 5.30 ± 0.86 nmol/mg protein/h on day 2 of pregnancy, which is comparable to level of non-pregnant control (5.27 ± 1.06 nmol/mg protein/h). PLA₂ activity was increased from day 3, reaching the maximum (15.00 ± 1.66 nmol/mg protein/h) on day 5 when implantation normally occurs in rats.

Moreover, PLA₂ activity was greater in the implant sites than in the non-implant sites of uterus both on days 6 and 7 (Table 1), and especially PLA₂ activity in the implant sites (13.40 ± 1.46 nmol/mg protein/h) was significantly greater than in the non-implant sites (7.70 ± 0.73 nmol/




Fig. 1. Uterine PLA₂ activity during the early pregnancy in rat. Data are expressed as mean \pm SEM of 6 to 8 animals. * $p < 0.05$ as compared with the value of non-pregnant group.

mg protein/h) of uterus on day 6 ($p < 0.05$).

Effects of estradiol or dbcAMP on uterine PLA₂ activity during the delayed implantation process

This experiment was performed to demonstrate whether estradiol stimulates uterine PGs synthesis by modulating phospholipase A₂ activity, an enzyme responsible for the arachidonic acid production which is a precursor for PGs synthesis (Fig. 2). During the delayed implantation process, the treatment of estradiol significantly increased PLA₂ activity at 12 hrs after estradiol administration (17.30 ± 2.11 nmol/mg protein/h, $p < 0.05$) as compared with progesterone

Table 1. Uterine PLA₂ activity in the implant and the non-implant sites of uterus on days 6 and 7 of pregnancy in rats

Day of pregnancy	PLA ₂ activity (nmol/mg protein/h)	
	Implant sites	Non-implant sites
6	$13.40 \pm 1.46^*$	7.70 ± 0.73
7	9.25 ± 1.03	7.24 ± 1.20

* $p < 0.05$ as compared with the value of PLA₂ activity in the non-implant sites on day 6 of pregnancy.




Fig. 2. Effects of estradiol, dbcAMP and theophylline on uterine PLA₂ activity during the delayed implantation process. Theophylline was pre-treated 2 hrs prior to estradiol administration. Data are expressed as mean \pm SEM of 6 to 8 animals. * $p < 0.05$. ** $p < 0.01$ as compared with the value at 0 hr.

only-treated group (8.55 ± 0.54 nmol/mg protein/h). At this time, uterine PGs were also increased concomitantly.

Furthermore, the treatment of dbcAMP instead of estradiol during the delayed implantation process advanced an increase in PLA₂ activity 4hrs. PLA₂ activity was significantly increased at 8 hrs after dbcAMP treatment (21.16 ± 3.28 nmol/mg protein/h, $p < 0.01$) as compared with progesterone only-treated group (8.55 ± 0.54 nmol/mg protein/h). PLA₂ activity was gradually decreased thereafter. The pretreatment of theophylline, phosphodiesterase inhibitor, 2 hrs prior to estradiol treatment resulted in an increase in PLA₂ activity as compared with estradiol-only treated group reaching the maximum at 12 hrs after estradiol administration.

Table 2 shows PLA₂ activity in the implant sites and the non-implant sites of uterus at 24 hrs

Table 2. Uterine PLA₂ activity in the implant sites and the non-implant sites at 24 hrs after estradiol or dbcAMP administration during the delayed implantation process

Treatments	PLA ₂ activity(nmol/mg protein/h)	
	Non-implant sites	Implant sites
Estradiol	4.74 ± 0.37	$11.89 \pm 2.63^*$
dbcAMP	4.08 ± 0.42	$13.88 \pm 2.54^*$

Data are expressed as mean \pm SEM of 6 to 8 animals.

* $p < 0.05$ as compared with the value of PLA₂ activity in the non-implant sites

following estradiol or dbcAMP administration during the delayed implantation process. PLA₂ activity was significantly greater in the implant sites than in the non-implant sites of uterus ($p < 0.05$). With the treatment of estradiol, PLA₂ activity in the implant sites was 2.5 fold greater than in the non-implant sites while after dbcAMP administration PLA₂ activity in the implant sites was 3.4 fold greater than in the non-implant sites.

Effect of indomethacin on estradiol or dbcAMP-induced uterine phospholipase A₂ activity during the delayed implantation process

The simultaneous treatment of indomethacin with estradiol or dbcAMP significantly suppressed both PGs synthesis while estradiol or dbcAMP-induced uterine PLA₂ activity was not altered (Table 3). These data suggest that estradiol or cAMP modulates mobilization of arachidonic acid from phospholipids by activating PLA₂ activity but does not affect subsequent cyclooxygenation of arachidonic acid.

DISCUSSION

In the present study, it was demonstrated that estradiol or cAMP stimulates uterine PGs synthesis by modulating PLA₂ activity. PLA₂ activity was increased at 12 hrs when PGs levels were increased after estradiol administration. The treatment of dbcAMP induced an increase in PLA₂ activity as well as PG synthesis 4 hrs in

Table 3. Effect of indomethacin on estradiol or dbcAMP-induced uterine PLA₂ activity during the delayed implantation process

Treatments	PGs(ng/100 mg tissue)		PLA ₂ activity (nmol/mg protein/h)
	PGE	PGF ₂ α	
Estradiol	53.46 ± 3.99	35.50 ± 2.71	17.30 ± 2.11
Estradiol+ID	$4.32 \pm 1.93^*$	$1.20 \pm 0.40^*$	17.55 ± 2.74
dbcAMP	62.50 ± 9.75	50.98 ± 7.04	21.66 ± 3.88
dbcAMP+ID	$6.19 \pm 0.78^*$	$4.68 \pm 0.77^*$	20.97 ± 3.06

PLA₂ activity was measured at 12 hrs after estradiol and at 8 hrs after dbcAMP administration. Data are expressed as mean \pm SEM of 6 to 8 animals.

* $p < 0.05$ as compared with the value of estradiol or dbcAMP-only treated group.

advance. In addition, higher PLA₂ activity was induced by the treatment of estradiol plus theophylline compared with estradiol-only treated group. According to Cox *et al.* (1982), uterine PLA₂ activity reached maximum just prior to implantation in rats, although the relative activity in the implant sites and non-implant sites of uterus was not examined. In rabbits, PLA₂ activity was greatly amplified on day 7 when trophoblast-endometrial apposition and attachment begin, and declined markedly within 24 hrs (Hoffman *et al.*, 1984). It was suggested that potential blastocyst-related stimuli for an increase in PLA₂ activity on day 5 in rats might include blastocyst-produced estrogen (Findlay, 1983; Kennedy, 1983) or histamine (Dey & Johnson, 1980). The effects of steroid hormones on uterine PLA₂ activity have been reported (Dey *et al.*, 1982; Pakrasi *et al.*, 1983), although little information is available on modulation of uterine PLA₂ activity during the implantation process in rats. Implantation of silastic capsules containing estradiol-17 β in hypophysectomized and progesterone-primed rats stimulated PLA₂ activity in endometrium (Dey *et al.*, 1982; Pakrasi *et al.*, 1983). These results support our results that estradiol might stimulate uterine PGs synthesis by way of modulating PLA₂ activity during the implantation process.

Exposure of cells to cAMP increased release of arachidonic acid, thereby stimulating PG production and this phenomenon has been described in several cell types (Dayal *et al.*, 1983; Baker *et al.*, 1985). Moreover, 8-bromo cAMP released arachidonic acid and increased PGE production in 3T3 fibroblasts (Lindgren *et al.*, 1978). In fat cell homogenates (Van den Bosh *et al.*, 1978) and human adherent synovial cells (Baker *et al.*, 1985), cAMP showed ability to stimulate PLA₂ activity. These results are consistent with our finding that dbcAMP increased uterine PLA₂ during the delayed implantation process. Higher activity of PLA₂ was induced by the treatment of estradiol plus theophylline as compared with estradiol-only treated group. The treatment of indomethacin suppressed estradiol- or dbcAMP-induced uterine PGs synthesis but did not change uterine PLA₂ activity. Since estradiol or dbcAMP stimulated PLA₂ activity, but did not stimulate PG synthesis in the presence indomethacin, it is unlikely that cyclooxygenase is a target for es-

tradiol or cAMP to stimulate PG synthesis.

In conclusion, the present study has demonstrated that estradiol stimulates uterine PLA₂ activity via cAMP mediation, thereby increasing PG synthesis during the delayed implantation process in rats.

REFERENCES

- Baker DG, Baumgarten DF, Bomalaski JS and Zurier RB: *Cyclic adenosine 3', 5' monophosphate stimulates prostaglandin E production by human adherent synovial cells. Prostaglandins* 30: 669, 1985
- Cox C, Cheng HC and Dey SK: *Phospholipase A₂ activity in the rat uterus during early pregnancy. Prostaglandins Leukotrienes Med* 8: 375, 1982
- Dayal V, Colman RW, Prakash O, Bose Ak and Sinha AK: *Cyclic AMP induces synthesis of prostaglandin E₁ in platelets. Biochem Biophys Acta* 759: 129, 1983
- Dey SK, Hoversland RC and Johnson DC: *Phospholipase A₂ activity in the rat uterus: Modulation by steroid hormones. Prostaglandins* 23: 619, 1982
- Dey Sk and Johnson SC: *Embryo-uterine interaction in implantation. Life Sciences* 27: 2381, 1980
- Findlay JK: *The endocrinology of the preimplantation period. Current Top Exp Endocrinol* 4: 35, 1983
- Hoffman LH, Davenport GR and Brash: *Endometrial prostaglandins and phospholipase A₂ activity related to implantation in rabbits: Effects of dexamethasine. Biol Reprod* 30: 544, 1984
- Kennedy TG: *Embryonic signals and the initiation of blastocyst implantation. Aust J Biol Sci* 36: 531, 1983
- Lee WH, Ryu K and Hong SS: *The role of prostaglandin in the process of implantation in rabbit. Yonsei Med J* 18: 205, 1985
- Lindgren JA, Claesson HE and Hammarstrom S: *Stimulation of arachidonic acid release and prostaglandin production in 3T3 fibroblasts by adenosine 3',5'-monophosphate. Adv in Prost Throm Res* 3: 167, 1978
- Pakrasi PL, Cheng HC and Dey SK: *Prostaglandins in the uterus: Modulation by steroid hormones. Prostaglandins* 26: 991, 1983

Phillips CA and Poyser L: *Studies on the involvement of prostaglandins in implantation in the rat. J Reprod Fert* 62: 73, 1981

Van Den Bosch H and Van Den Besselaar AMHP: *Intracellular formation and removal of lysophospholipids. Adv in Throm Res* 3: 69, 1978

Yoon M, Kim C, Choe RS and Ryu K: *Mediation of cAMP in the estradiol-induced prostaglandin*

synthesis during the delayed implantation process in rats. Kor J Pharmacol(in press), 1991

Yoon M and Ryu K: *Studies in the concentrations of receptors for ovarian steroids, prostaglandins and cAMP in uterine tissue during the period of implantation in rats. Kor J Fertil Steril* 14: 43, 1987

= 국문초록 =

흰쥐의 착상기간중 Estradiol이 자궁의 Phospholipase A₂ 활성도에 미치는 영향

연세대학교 의과대학 약리학교실, 내분비연구실* 및 이과대학 생물학과**

윤미정* · 김창미* · 최임순** · 유경자

본 연구에서는 흰쥐의 수정란 착상시기에 estradiol이 prostaglandins(PGs) 합성의 전구체인 arachidonic acid를 생성하는데 관여하는 phospholipase A₂(PLA₂)의 활성도를 조절함으로써 PGs의 합성을 촉진하는가를 조사하여 다음과 같은 결과를 얻었다.

자궁의 PLA₂ 활성도는 수정란이 착상하는 시기인 임신 제 5일에 증가되었으며, 비착상부위에서 보다는 착상부위에서 더 높은 것으로 나타났다. Delayed implantation model에서, PLA₂ 활성도는 estradiol을 투여한 지 11시간후에 증가되었으며, dbcAMP를 투여한지 8시간후에 증가되었다. 또한 estradiol을 투여하기 2시간전에 phosphodiesterase inhibitor인 theophylline을 투여하면 estradiol만 투여한것에 비하여 PLA₂ 활성도가 증가되었다. Estradiol 또는 dbcAMP와 함께 indomethacin을 투여하면 자궁의 PGs합성은 억제되었으나 PLA₂ 활성도에는 영향을 주지않았다.

이상의 결과로 보아 흰쥐의 착상시기에 estradiol은 cAMP를 매개로하여 자궁의 PLA₂ 활성도를 촉진하므로써 PGs의 합성을 증가시키는 것으로 생각된다.